AstraZeneca Stock Rating Reaffirmed by Jefferies Group (AZN)
AstraZeneca (LON: AZN)‘s stock had its “hold” rating reaffirmed by research analysts at Jefferies Group in a report released on Wednesday. They currently have a $44.80 (3000 GBX) target price on the stock.
AstraZeneca opened at 3070.00 on Wednesday. AstraZeneca has a 52-week low of GBX 2578.50 and a 52-week high of GBX 3171.50. The stock’s 50-day moving average is currently GBX 2919.40. The company’s market cap is £38.283 billion.
A number of other analysts have also recently weighed in on AZN. Analysts at JP Morgan Cazenove reiterated an “underweight” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a $41.07 price target on the stock. Separately, analysts at Barclays Capital reiterated an “equal weight” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a $47.04 price target on the stock. Finally, analysts at Swedbank AB downgraded shares of AstraZeneca to a “sell” rating in a research note to investors on Friday, March 8th. They now have a $40.22 price target on the stock.
AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.